0784 SLEEP VALIDITY OF A NON-CONTACT BEDSIDE MOVEMENT AND RESPIRATION-SENSING DEVICE

Abstract Introduction: Expanding recognition of sleep’s importance has created a vast commercial market for sleep monitoring devices. Device reliability is generally presumed, despite low performance: typically, high sleep-detecting sensitivity (≥95%) but poor wake-detecting specificity (≤40%). To d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sleep (New York, N.Y.) N.Y.), 2017-04, Vol.40 (suppl_1), p.A290-A291
Hauptverfasser: Schade, MM, Bauer, CE, Murray, BR, Gahan, L, Doheny, EP, Kilroy, H, Zaffaroni, A, Montgomery-Downs, HE
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Introduction: Expanding recognition of sleep’s importance has created a vast commercial market for sleep monitoring devices. Device reliability is generally presumed, despite low performance: typically, high sleep-detecting sensitivity (≥95%) but poor wake-detecting specificity (≤40%). To describe the validity of a novel device and illustrate the impact of algorithm changes in a fast-adapting market, we compared versions 1 (V1) and 2 (V2) of the S+ by ResMed bedside monitor against PSG. Methods: Healthy adult sleepers underwent standard PSG, time-synchronized with the non-contact bedside device. Epoch-by-epoch V1 (N=27) and V2 (N=22) validity, and within-subject changes from V1 to V2 (N=22), were tested. Subjects were 41% female, 97% Caucasian, 15% married, aged 29.1(±12) years with a BMI of 27(±6); they had 16(±3) years education and median income $65,000. Results: Total sleep time [TST] per PSG was 338(±57) minutes with normal sleep architecture. Full sleep staging agreement of V1 was 61(±9)%, while V2 was 62(±7)%. For sleep/wake comparison, sleep sensitivity of V1 and V2 were 93(±6)% and 94(±4)%, while wake specificity of V1 and V2 were 70(±19)% and 73(±20)%. Specificity of V1 and V2 for WBSO were 88(±16)% and 90(±15)%; for WASO they were 51(±23)% and 53(±22)%, respectively. Analysis of within-­subject changes follows: overall sleep sensitivity of V2 was significantly lower (p=.026); WBSO specificity did not differ; V2 WASO specificity was significantly higher (p=.022). Stage-specific results and an actigraphy comparison will be presented at the meeting. Conclusion: Relative to other published evaluations of commercially available, wearable sleep-tracking devices, this bedside device better identifies WBSO - a major challenge in this industry. There is still room to improve WASO specificity of this and all commercial sleep trackers. 100% accuracy is an unrealistic goal; rather, devices should approach PSG human inter-scorer reliability of ~81% for wake specificity. Support (If Any): Equipment, supplies, participant compensation, and student stipends were provided by ResMed. The faculty supervisor received no salary support or compensation from ResMed.
ISSN:0161-8105
1550-9109
DOI:10.1093/sleepj/zsx050.783